Immix Biopharma, Inc.(IMMX)

POST8.820.13+1.50%19:46 EDT

8.69+0.17+2.00%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Immix Biopharma Initiated at Buy by Needham
  Dow Jones · 07-22
  Immix Biopharma Initiated at Buy by Needham
- Needham Initiates Immix Biopharma at Buy With $21 Price Target
  MT Newswires Live · 07-22
  Needham Initiates Immix Biopharma at Buy With $21 Price Target
- Immix Biopharma Inc : Needham Initiates Coverage with Buy Rating; Target Price $21
  THOMSON REUTERS · 07-22
  Immix Biopharma Inc : Needham Initiates Coverage with Buy Rating; Target Price $21
- Immix Biopharma Terminates Richard Graydon Employment
  Reuters · 07-20
  Immix Biopharma Terminates Richard Graydon Employment
- Immix Biopharma - Richard Graydon Terminated from Immix Biopharma as of July 17, 2026 - SEC Filing
  THOMSON REUTERS · 07-20
  Immix Biopharma - Richard Graydon Terminated from Immix Biopharma as of July 17, 2026 - SEC Filing
- Immix Biopharma Posts Corporate Presentation Highlighting Nxc-201 CAR-T in Relapsed/refractory AL Amyloidosis
  Reuters · 07-03
  Immix Biopharma Posts Corporate Presentation Highlighting Nxc-201 CAR-T in Relapsed/refractory AL Amyloidosis
- Immix Biopharma Inc : Bofa Global Research Initiates Coverage With Buy Rating; Price Objective $27
  THOMSON REUTERS · 06-18
  Immix Biopharma Inc : Bofa Global Research Initiates Coverage With Buy Rating; Price Objective $27
- BofA Initiates Immix Biopharma at Buy With $27 Price Target
  MT Newswires Live · 06-18
  BofA Initiates Immix Biopharma at Buy With $27 Price Target
- Immix Biopharma Initiated at Outperform by LifeSci Capital
  Dow Jones · 06-18
  Immix Biopharma Initiated at Outperform by LifeSci Capital
- Immix Biopharma publishes corporate presentation highlighting NXC-201 CAR-T in relapsed/refractory AL amyloidosis
  Reuters · 06-18
  Immix Biopharma publishes corporate presentation highlighting NXC-201 CAR-T in relapsed/refractory AL amyloidosis
- Immix Biopharma shareholders elect directors at annual meeting
  Reuters · 05-30
  Immix Biopharma shareholders elect directors at annual meeting
- Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biohaven Ltd. (BHVN) and Immix Biopharma (IMMX)
  TIPRANKS · 05-27
  Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biohaven Ltd. (BHVN) and Immix Biopharma (IMMX)
- Immix Biopharma closes $150 million common stock offering at $8.94 per share
  Reuters · 05-23
  Immix Biopharma closes $150 million common stock offering at $8.94 per share
- Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
  THOMSON REUTERS · 05-23
  Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
- Immix Biopharma Is Maintained at Buy by HC Wainwright & Co.
  Dow Jones · 05-23
  Immix Biopharma Is Maintained at Buy by HC Wainwright & Co.
- Immix Biopharma, Inc. : H.c. Wainwright Raises Target Price to $20 From $15
  THOMSON REUTERS · 05-22
  Immix Biopharma, Inc. : H.c. Wainwright Raises Target Price to $20 From $15
- Immix Biopharma Prices $150 Million Stock Offering
  MT Newswires Live · 05-21
  Immix Biopharma Prices $150 Million Stock Offering
- Immix Biopharma prices USD 150 million follow-on stock offering at USD 8.94/share
  Reuters · 05-21
  Immix Biopharma prices USD 150 million follow-on stock offering at USD 8.94/share
- Immix Biopharma Inc: Pricing of Offering of 16.8 Mln Shares at Price to Public of $8.94 per Share
  THOMSON REUTERS · 05-21
  Immix Biopharma Inc: Pricing of Offering of 16.8 Mln Shares at Price to Public of $8.94 per Share
- Immix Biopharma Inc - Net Proceeds to Fund Nxc-201 Development, Working Capital, and Corporate Purposes
  THOMSON REUTERS · 05-21
  Immix Biopharma Inc - Net Proceeds to Fund Nxc-201 Development, Working Capital, and Corporate Purposes
Company Profile
Company Name
Immix Biopharma, Inc.
Market
NASDAQ
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.immixbio.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
- 07-20
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 06-05
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 05-29
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 05-21
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 05-21
  [Supp]Public Prospectus
  Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
  Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
- 05-21
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 05-15
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 05-07
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 05-05
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 03-30
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 03-27
  [Rev.]Annual Report
  Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
  Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
- 03-25
  Employee Stock Ownership
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans
- 03-25
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 03-25
  Annual Report
  Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
  Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
- 01-17
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence

1D
5D
Day
Week
Month

Loading ...

High

9.39

Open

8.63

Volume%

0.86

Low

8.58

8.52

T/O Rate

3.50%

To The Moon

Immix Biopharma, Inc.(IMMX)

Company Profile

Most Discussed